Robbins Andrew R 4
4 · Cogent Biosciences, Inc. · Filed Dec 19, 2025
Insider Transaction Report
Form 4
Robbins Andrews R
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-12-17+185,000→ 185,000 total - Award
Common Stock
2025-12-17+840,000→ 1,025,000 total - Tax Payment
Common Stock
2025-12-17$39.45/sh−367,497$14,497,757→ 657,503 total - Award
Stock Option (Right to Buy)
2025-12-17+245,000→ 245,000 totalExercise: $39.45Exp: 2035-12-17→ Common Stock (245,000 underlying)
Footnotes (5)
- [F1]Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
- [F2]Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").
- [F3]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.